The owners of aland Health Holding, including private equity firms including Affinity Equity Partners and Goldman Sachs Capital Partners, are preparing to sell their combined controlling stake in a deal expected to value the company at over $1.5bn, according to a report by Reuters.
Founder and Chairman Chang Liang holds roughly 60% of the China-based global nutritional supplements group, while the remainder is owned by PE and growth investors. The potential sale – still in its early stages – has drawn initial interest from both strategic acquirers and PE firms, according to one source.
Aland is on track to deliver around $150m EBITDA in 2025, with its US business, International Vitamin Corporation (IVC), seen as a key attraction for bidders seeking domestic production capabilities and exposure to the booming wellness market. The global nutritional supplements sector, valued at $485.6bn in 2024, is forecast to grow at a 6.4% CAGR to $704.3bn by 2030.
Founded in 1998, aland operates 11 manufacturing sites and four R&D centres across Asia, North America, and Europe, supplying branded and private-label products to retailers including Walmart and Costco.
